Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last Hour:
Last 24 Hours:

TRACON Pharmaceuticals to host key opinion leader webinar on envafolimab for the treatment of sarcoma on July 17

% of readers think this story is Fact. Add your two cents.

TRACON Pharmaceuticals Inc. (NASDAQ:TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, has said that it will host a key opinion leader (KOL) webinar on envafolimab for the treatment of sarcoma on Friday, July 17, 2020, at 11.00am Eastern Time. 

The webinar will feature a presentation by Robert Maki, MD, PhD, of the University of Pennsylvania School of Medicine, who will discuss the current treatment landscape and unmet medical need in treating patients with sarcoma. He will be available to answer questions at the conclusion of the event.

READ: TRACON Pharmaceuticals says separate study buoys potential of envafolimab combination to treat sarcoma

Dr Maki is a graduate of Cornell University Medical College, and has a PhD. in Immunology from Cornell University Graduate School of Medical Sciences. He completed his internship and residency at Brigham and Women’s Hospital and fellowship in medical oncology at the Dana Farber Cancer Institute. 

His expertise includes the more than 70 types of bone and soft tissue sarcomas, and he is the co-author of ‘Management of Soft Tissue Sarcoma’, from Springer Books.

TRACON’s chief executive officer, Charles Theuer, MD, PhD, will also provide an update on envafolimab, the company’s lead product candidate for treating patients with sarcoma. Envafolimab is a novel, single-domain antibody against PD-L1 that is administered by subcutaneous injection without the need for an adjuvant. 

It is currently being studied in China in a Phase 2 registration trial as a single agent in MSI-H/dMMR colorectal cancer patients, in combination with gemcitabine and oxaliplatin in a Phase 3 registration trial in biliary tract cancer, as well as in several Phase 1 trials in the US and Japan. 

Having agreed with the US Food and Drug Administration (FDA) on trial design, TRACON intends to initiate the ENVASARC pivotal study of envafolimab in the sarcoma subtypes of undifferentiated pleomorphic sarcoma and myxofibrosarcoma in the second half of 2020.

Contact the author at [email protected]

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at

Order by Phone at 888-809-8385 or online at

Get our Free Ebook, "Suppressed Health Secrets"  with  Natural Cures THEY don't want you to know!

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Organic Hemp Extract (CBD) - Full Spectrum high CBD (3300mg) hemp extract eases stiff joints, relieves stress and more!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Load more ...




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.